戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ld be treated as a form of uterine papillary serous cancer.
2  management of early stage uterine papillary serous cancer.
3 reening group were diagnosed with high-grade serous cancer.
4 (STIC), the postulated origin for high-grade serous cancer.
5 were particularly common (23%) in high-grade serous cancers.
6 parent for women >50 and women with invasive serous cancers.
7 el overall and for epithelial and high-grade serous cancers.
8 ssive endometrial cancers, including uterine serous cancer and uterine carcinosarcoma, which together
9 xpected number was 5.27 (95% CI, 1.78-19.29) serous cancers and 8.68 (95% CI, 3.36-26.58) epithelial
10 n the literature regarding uterine papillary serous cancer are that a potential precursor lesion, ser
11                                   High-grade serous cancers are characterized by few driver point mut
12                          Ovarian and uterine serous cancers are extremely lethal diseases that often
13 -screen comparisons of women with high-grade serous cancer at censorship in multimodal screening vers
14                               In a number of serous cancer cell lines with a dysfunctional p53 pathwa
15 at miR-200b had an overall elevated level in serous cancer compared with controls, whereas miR-429 wa
16 erscores STIC as a possible target for early serous cancer detection and prevention.
17 vidence that screening can detect high-grade serous cancer earlier and lead to improved short-term tr
18 alpingectomy on the prevention of high-grade serous cancer (HGSC) at the population level is currentl
19 d a case control study to predict high-grade serous cancer (HGSC) using artificial intelligence metho
20                                   High-grade serous cancer (HGSC), the most common subtype of ovarian
21 ian and breast cancer cell lines, high-grade serous cancer (HGSC)-derived organoids, and patient-deri
22 ical efficacy in the treatment of high-grade serous cancers (HGSC).
23 m randomisation of 779 women with high-grade serous cancer in the multimodal and no screening groups
24 misation was longer in women with high-grade serous cancer in the multimodal screening group than in
25 en implicated as a site of origin for pelvic serous cancers, including high-grade serous tubo-ovarian
26                            Uterine papillary serous cancer is an extremely aggressive cancer, the opt
27  that may recur as chemo-resistant low-grade serous cancer (LGSC).
28 platinum-sensitive recurrent EOC, peritoneal serous cancer, or fallopian tube cancer.
29 nded, especially for women with stage III or serous cancers, or both, as part of shared decision maki
30 umors, increasing trends in risk of invasive serous cancer (p = 0.018), and particularly endometrioid
31 4.1% of patients overall, including 16.6% of serous cancer patients (high-gradeserous, 17.1%); [corre
32 ic women with BRCA mutations and linked to a serous cancer precursor in the fimbria.
33 ctomized mice continue to develop high-grade serous cancers, removal of the fallopian tube at an earl
34                    Stage I uterine papillary serous cancer requires aggressive treatment, including s
35                   The greatest proportion of serous cancer risk in BRCA mutation-positive women shoul
36    Large-scale genomic studies of high-grade serous cancer, the most common histotype, have identifie
37 emonstrate challenges for risk prediction of serous cancers, the most fatal subtype.
38    Besides the clinical resemblance to human serous cancers, these fallopian tube cancers highly expr
39  of endometrial carcinoma, uterine papillary serous cancer (UPSC).
40 l survival benefit for women with high-grade serous cancer was small, most likely due to only modest